Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer. Bristol Myers on Friday ...

The panelist discusses the case of a 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC). The patient has a history of metabolic dysfunction-associated steatohepatitis managed ...

US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus ...

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), ...

Squibb announced that the European Commission has approved Opdivo plus Yervoy for the first-line treatment of adult ...

AstraZeneca Pharma India Ltd has received the nod from the Central Drugs Standard Control Organisation (CDSCO) to import and ...

AstraZeneca Pharma India has announced that the Company has received permission from the CentralDrugs Standard Control ...

AstraZeneca Pharma India Ltd has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute the cancer treatment drug Durvalumab in India. This approval ...

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...